7 results about "Hepatitis D" patented technology

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The present invention relates to the use of methylene blue in the treatment of treatment of hepatitis B (HBV) and / or hepatitis D (HDV) infection of a human patient as well as pharmaceutical compositions applicable in this treatment.

The present invention relates to a diagnostic kit for hepatitis D, which detects an antibody against hepatitis D virus (HDV) in a sample to rapidly and accurately detect the presence or absence of HDV infection and, more specifically, to a diagnostic kit for hepatitis D, comprising a recombinant HDV antigen.

The invention relates to an anti-HBsAg antibody, an antibody fragment and application thereof in preventing and treating hepatitis D virus infection and related diseases. The present invention provides a method of neutralizing hepatitis delta virus infection comprising administering an effective amount of the antibody or antigen-binding fragment thereof to a patient in need thereof by injection or infusion.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The invention discloses an application of siRNA (small interfering Ribonucleic Acid) in preparation of a medicine for treating hepatitis. A positive-sense strand of the siRNA has a nucleotide sequence as shown in SEQ ID NO: 1, at least 85% of bases of an antisense strand of the siRNA and the positive-sense strand are complementary, and hepatitis is hepatitis D liver or hepatitis B and hepatitis D liver. The siRNA inhibits the duplication of liver D by inhibiting the concentration of HBV S protein in vivo.

The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.